Source: International Congress 2019 – Treatment of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
A. Alves (Vila Nova de Gaia , Portugal), I. Sucena (Vila Nova de Gaia , Portugal), M. Dias (Vila Nova de Gaia , Portugal), D. Coutinho (Vila Nova de Gaia , Portugal), T. Costa (Vila Nova de Gaia , Portugal), E. Silva (Vila Nova de Gaia , Portugal), S. Conde (Vila Nova de Gaia , Portugal), S. Campainha (Vila Nova de Gaia , Portugal), A. Barroso (Vila Nova de Gaia , Portugal). Impact of antibiotics on immunotherapy response in lung cancer patients. 371

Member's Comments

No comment yet.

Related content which might interest you: Impact of COPD on prognosis of lung cancer: the prespective of immunotherapy treatment Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Re-challenge of immunotherapy in a lung cancer patient Source: Virtual Congress 2021 – Lung cancer grand round Year: 2021 How to evaluate the immune status of lung cancer patients before immunotherapy Source: Breathe, 13 (4) 291; 10.1183/20734735.001917 Year: 2017 Eosinophilia in lung cancer patients treated with immunotherapy Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019 Assessment of lung cancer related symptoms and chemotherapy related side effects in a group of patients with advanced lung cancer receiving palliative chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006 Effects of helium/oxygen therapy on QoL in lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 455s Year: 2002 Small cell lung cancer patients and their responses to treatment Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004 Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study Source: ERJ Open Res, 6 (1) 00189-2019; 10.1183/23120541.00189-2019 Year: 2020 Boosting immunotherapy in lung cancer  Source: International Congress 2017 – ME9 Boosting immunotherapy in lung cancer Year: 2017 Effect of physical characteristics on patient response to nivolumab in non-small-cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Second-line treatment patients at relapse of disseminated small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 395s Year: 2001 Evaluation of outpatient infections in lung cancer patients treated with chemotherapy and/or radiotherapy Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer Year: 2012 The effects of different chemotherapy regimes in the patients with advanced lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 755s Year: 2006 Characteristics, incidence, risk factors, and practical management of pneumonitis associated with anti-PD-1 immunotherapy in patients with non-small cell lung cancer Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer Source: ERJ Open Res, 4 (2) 00120-2017; 10.1183/23120541.00120-2017 Year: 2018 Impact of radiotherapy on survival rates in chemotherapy treated non small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Targeted therapy for lung cancer Source: Eur Respir J 2015; 46: 1239-1241 Year: 2015 Second-line therapy in elderly patients with advanced nonsmall cell lung cancer Source: Eur Respir J 2014; 43: 240-249 Year: 2004 Outcome after pneumonectomy in non small cell lung cancer patients receiving a neoadjuvant therapy Source: Eur Respir J 2004; 24: Suppl. 48, 478s Year: 2004